Skip to main content

Vyndamax for Cardiomyopathy of Transthyretin-Mediated Amyloidosis User Reviews

Rating: 7.7

Vyndamax has an average rating of 7.7 out of 10 from a total of 3 reviews for the treatment of cardiomyopathy of transthyretin-mediated amyloidosis. 33% of reviewers reported a positive experience, while 0% reported a negative experience.

10
33%
9
0%
8
0%
7
33%
6
33%
5
0%
4
0%
3
0%
2
0%
1
0%
  • ken...
  • Taken for 2 to 5 years
  • April 24, 2025

"I am 77 years of age. I have been taking Vyndamax, 61 mg daily, for over 2 1/2 years. I haven't had any noticeable adverse side effects from the drug. I have not suffered any hospitalizations since beginning the drug. I had two ablation procedures to correct atrial fibrillation prior to the amyloidosis diagnosis confirmation and beginning to take Vyndamax. I am able to continue to exercise regularly and continue normal activities. Annual echocardiograms show mild heart failure but have not progressed abnormally. I am pleased with the impact of the Vyndamax on my general health and prognosis. Unfortunately, it does not slow the aging process."

10 / 10
Was this helpful?YesNo
1 Report
  • Ano...
  • Taken for 1 to 2 years
  • April 23, 2025

"Taking Vyndamax on the recommendation of my cardiologist, however I have no idea if the medication is working as described and if so to what extent. I was not aware of an alternative medication until I saw an advertisement."

6 / 10
Was this helpful?YesNo
0 Report
  • Ran...
  • Taken for 1 to 6 months
  • July 26, 2024

"I had lost a lot of weight. I am in my third month using the medication, seem to have a bigger, better appetite and have put on about 5 needed pounds in the last 3 weeks. Wondering if that is a positive effect of the medication?"

7 / 10
Was this helpful?YesNo
1 Report

Frequently asked questions

Are you taking this medicine?

Your review helps others make informed decisions.
Write a review
Reviews may be edited to correct grammar/spelling or remove inappropriate content. Reviews appearing to come from parties with a vested interest are not published. This information is not intended to endorse any medication and should not replace the expertise and judgment of healthcare professionals.